Protective protein/cathepsin A down-regulates osteoclastogenesis by associating with and degrading NF-κB p50/p65

Felix R, Cecchini M, Hofstetter W, Elford P, Stutzer A, Fleisch H (1990) Impairment of macrophage colony-stimulating factor production and lack of resident bone marrow macrophages in the osteopetrotic op/op mouse. J Bone Miner Res 5:781–789 Kodama H, Yamasaki A, Nose M, Niida S, Ohgame Y, Abe M, Kumegawa M, Suda T (1991) Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J Exp Med 173:269–272 Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602 Lacey D, Timms E, Tan H, Kelley M, Dunstan C, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle W (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176 Kong Y, Yoshida H, Sarosi I, Tan H, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos A, Van G, Itie A, Khoo W, Wakeham A, Dunstan C, Lacey D, Mak T, Boyle W, Penninger J (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323 Franzoso G, Carlson L, Xing L, Poljak L, Shores E, Brown K, Leonardi A, Tran T, Boyce B, Siebenlist U (1997) Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482–3496 Darnay B, Haridas V, Ni J, Moore P, Aggarwal B (1998) Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK)Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 273:20551–20555 Matsuo K, Owens J, Tonko M, Elliott C, Chambers T, Wagner E (2000) Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24:184–187 Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner E, Mak T, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889–901 Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast differentiation. Bone 40:251–264 Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277:41147–41156 Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428:758–763 Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner E, Mak T, Serfling E, Takayanagi H (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202:1261–1269 Jackman H, Tan F, Tamei H, Beurling-Harbury C, Li X, Skidgel R, Erdös E (1990) A peptidase in human platelets that deamidates tachykinins. Probable identity with the lysosomal “protective protein”. J Biol Chem 265:11265–11272 Jackman H, Morris P, Deddish P, Skidgel R, Erdös E (1992) Inactivation of endothelin I by deamidase (lysosomal protective protein). J Biol Chem 267:2872–2875 Hanna W, Turbov J, Jackman H, Tan F, Froelich C (1994) Dominant chymotrypsin-like esterase activity in human lymphocyte granules is mediated by the serine carboxypeptidase called cathepsin A-like protective protein. J Immunol 153:4663–4672 Verheijen F, Palmeri S, Hoogeveen A, Galjaard H (1985) Human placental neuraminidase. Activation, stabilization and association with beta-galactosidase and its protective protein. Eur J Biochem 149:315–321 D’Agrosa R, Hubbes M, Zhang S, Shankaran R, Callahan J (1992) Characteristics of the beta-galactosidase-carboxypeptidase complex in GM1-gangliosidosis and beta-galactosialidosis fibroblasts. Biochem J 285(Pt 3):833–838 d’Azzo A, Andria G, Striscuiglio P, Galjaard H (2001) Metabolic and molecular bases of inherited disease, 8th edn. New York, pp 3811–3826 van der Spoel A, Bonten E, d’Azzo A (1998) Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO J 17:1588–1597 Bonten E, Wang D, Toy J, Mann L, Mignardot A, Yogalingam G, d’Azzo A (2004) Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis. FASEB J 18:971–973 Tatano Y, Takeuchi N, Kuwahara J, Sakuraba H, Takahashi T, Takada G, Itoh K (2006) Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies. J Med Invest 53:103–112 Matsuda K (1976) Studies on cathepsins of rat liver lysosomes. III. Hydrolysis of peptides, and inactivation of angiotensin and bradykinin by cathepsin A. J Biochem 80:659–669 Itoh K, Oyanagi K, Takahashi H, Sato T, Hashizume Y, Shimmoto M, Sakuraba H (2000) Endothelin-1 in the brain of patients with galactosialidosis: its abnormal increase and distribution pattern. Ann Neurol 47:122–126 Jimi E, Ikebe T, Takahashi N, Hirata M, Suda T, Koga T (1996) Interleukin-1 alpha activates an NF-kappaB-like factor in osteoclast-like cells. J Biol Chem 271:4605–4608 Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T (1998) Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 273:8799–8805 Wei S, Teitelbaum S, Wang M, Ross F (2001) Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 142:1290–1295 Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3:1285–1289 Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20:1271–1280 Hayashi T, Kaneda T, Toyama Y, Kumegawa M, Hakeda Y (2002) Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J Biol Chem 277:27880–27886 Sato T, Watanabe K, Masuhara M, Hada N, Hakeda Y (2007) Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Metab 25:19–27 Katunuma N (1997) Mechanism and regulation of bone resorption by osteoclasts. Curr Top Cell Regul 35:179–192 Tezuka K, Tezuka Y, Maejima A, Sato T, Nemoto K, Kamioka H, Hakeda Y, Kumegawa M (1994) Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem 269:1106–1109 Takuma A, Kaneda T, Sato T, Ninomiya S, Kumegawa M, Hakeda Y (2003) Dexamethasone enhances osteoclast formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 278:44667–44674 Tjelle T, Brech A, Juvet L, Griffiths G, Berg T (1996) Isolation and characterization of early endosomes, late endosomes and terminal lysosomes: their role in protein degradation. J Cell Sci 109(Pt 12):2905–2914 Ishibashi A, Tsuboi R, Shinmei M (1984) beta-Galactosidase and neuraminidase deficiency associated with angiokeratoma corporis diffusum. Arch Dermatol 120:1344–1346 Yamano T, Shimada M, Sugino H, Dezawa T, Koike M, Okada S, Yabuuchi H (1985) Ultrastructural study on a severe infantile sialidosis (beta-galactosidase-alpha-neuraminidase deficiency). Neuropediatrics 16:109–112 Nordborg C, Kyllerman M, Conradi N, Mansson J (1997) Early-infantile galactosialidosis with multiple brain infarctions: morphological, neuropathological and neurochemical findings. Acta Neuropathol 93:24–33 Cuervo A, Mann L, Bonten E, d’Azzo A, Dice J (2003) Cathepsin A regulates chaperone-mediated autophagy through cleavage of the lysosomal receptor. EMBO J 22:47–59 Bidere N, Lorenzo H, Carmona S, Laforge M, Harper F, Dumont C, Senik A (2003) Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J Biol Chem 278:31401–31411 Chen W, Li N, Chen T, Han Y, Li C, Wang Y, He W, Zhang L, Wan T, Cao X (2005) The lysosome-associated apoptosis-inducing protein containing the pleckstrin homology (PH) and FYVE domains (LAPF), representative of a novel family of PH and FYVE domain-containing proteins, induces caspase-independent apoptosis via the lysosomal-mitochondrial pathway. J Biol Chem 280:40985–40995 Taha T, Kitatani K, Bielawski J, Cho W, Hannun Y, Obeid L (2005) Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 280:17196–17202 Bulynko Y, Hsing L, Mason R, Tremethick D, Grigoryev S (2006) Cathepsin L stabilizes the histone modification landscape on the Y chromosome and pericentromeric heterochromatin. Mol Cell Biol 26:4172–4184 Kerssen D, Hambruch E, Klaas W, Platta H, de Kruijff B, Erdmann R, Kunau W, Schliebs W (2006) Membrane association of the cycling peroxisome import receptor Pex5p. J Biol Chem 281:27003–27015 Leon C, Nandan D, Lopez M, Moeenrezakhanlou A, Reiner N (2006) Annexin V associates with the IFN-gamma receptor and regulates IFN-gamma signaling. J Immunol 176:5934–5942 Xing L, Bushnell T, Carlson L, Tai Z, Tondravi M, Siebenlist U, Young F, Boyce B (2002) NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 17:1200–1210 Ruocco M, Maeda S, Park J, Lawrence T, Hsu L, Cao Y, Schett G, Wagner E, Karin M (2005) IκB kinase (IKK)β, but not IKKa is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 201:1677–1687 Novack D, Yin L, Hagen-Stapleton A, Schreiber R, Goeddel D, Ross F, Teitelbaum S (2003) The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med 198:771–781 Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack D (2005) NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 115:1848–1854 Cuervo A, Hu W, Lim B, Dice J (1998) IkappaB is a substrate for a selective pathway of lysosomal proteolysis. Mol Biol Cell 9:1995–2010